Please login to the form below

Not currently logged in
Email:
Password:

PixarBio promotes Glenn Reiser

He becomes vice president of external affairs

US specialty biotechnology company PixarBio has promoted Glenn Reiser to vice president of external affairs.

In his new role, Reiser will be responsible for managing the firm's global reputation with a particular focus on developing and delivering integrated communications in alignment with its products pipeline.

 He first joined PixarBio in August last year as director for business development bringing 15 years of experience from Centocor Biotech of Johnson & Johnson, Endo Health Solutions and Pacira Pharmaceuticals.

Frank Reynolds, chief executive officer of PixarBio, said: “Glenn has overachieved in his role at PixarBio. We recruited Glenn from Pacira Pharmaceuticals to support product roll-out, but we have tapped into his unlocked talents and are expanding his role in our company.

“He brings industry experience and business acumen to every meeting and keeps everyone on their toes. We will succeed in short order and Glenn is a key fit for our team's success.”

4th April 2016

From: Sales, Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics